No data available.
Please log in to see this content.
You have no subscription access to this content.
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
The full text of this article is not currently available.
investigation of the therapeutic effect of pulsed focused ultrasound on tumor growth
1.T. J. Dubinsky, C. Cuevas, M. K. Dighe, O. Kolokythas, and J. H. Hwang, “High-intensity focused ultrasound: Current potential and oncologic applications,” Am. J. Roentgenol. 190, 191–199 (2008).
4.K. U. Kohrmann, M. S. Michel, J. Gaa, E. Marlinghaus, and P. Alken, “High intensity focused ultrasound as noninvasive therapy for multilocal renal cell carcinoma: Case study and review of the literature,” J. Urol. 167, 2397–2403 (2002).
5.C. M. C. Tempany, E. A. Stewart, N. McDannold, B. J. Quade, F. A. Jolesz, and K. Hynynen, “MR imaging-guided focused ultrasound surgery of uterine leiomyomas: A feasibility study,” Radiology 226, 897–905 (2003).
6.R. O. Illing, J. E. Kennedy, F. Wu, G. R. ter Haar, A. S. Protheroe, P. J. Friend, F. V. Gleeson, D. W. Cranston, R. R. Phillips, and M. R. Middleton, “The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a western population,” Br. J. Cancer 93, 890–895 (2005).
7.F. Wu, Z. B. Wang, H. Zhu, W. Z. Chen, J. Z. Zou, I. Bai, K. Q. Li, C. B. Jin, F. L. Xie, and H. Su, “Feasibility of US-guided high-intensity focused ultrasound treatment in patients with advanced pancreatic cancer: Initial experience,” Radiology 236, 1034–1040 (2005).
8.E. A. Stewart, J. Rabinovici, C. M. C. Tempany, Y. Inbar, J. Hindley, L. Regan, B. Gastout, G. Hesley, H. S. Kim, S. Hengst, and W. M. Gedroye, “Clinical outcomes of focused ultrasound surgery for the treatment of uterine fibroids,” Fertil. and Steril. 85, 22–29 (2006).
10.J. L. Nelson, B. L. Roeder, J. C. Carmen, F. Roloff, and W. G. Pitt, “Ultrasonically activated chemotherapeutic drug delivery in a rat model,” Cancer Res. 62, 7280–7283 (2002).
11.K. M. Dittmar, J. W. Xie, F. Hunter, C. Trimble, M. Bur, V. Frenkel, and K. C. P. Li, “Pulsed high-intensity focused ultrasound enhances systemic administration of naked DNA in squamous cell carcinoma model: Initial experience,” Radiology 235, 541–546 (2005).
12.E. L. Yuh, S. G. Shulman, S. A. Mehta, J. W. Xie, L. L. Chen, V. Frenkel, M. D. Bednarski, and K. C. P. Li, “Delivery of systemic chemotherapeutic agent to tumors by using focused ultrasound: Study in a murine model,” Radiology 234, 431–437 (2005).
13.H. A. Hancock, L. H. Smith, J. Cuesta, A. K. Durrani, M. Angstadt, M. L. Palmeri, E. Kimmel, and V. Frenkel, “Investigations into pulsed high-intensity focused ultrasound-enhanced delivery: Preliminary evidence for a novel mechanism,” Ultrasound Med. Biol. 35, 1722–1736 (2009).
14.L. L. Chen, Z. M. Mu, P. Hachem, C. M. Ma, A. Wallentine, and A. Pollack, “MR-guided focused ultrasound: Enhancement of intratumoral uptake of H-3 -docetaxel in vivo,” Phys. Med. Biol. 55, 7399–7410 (2010).
15.Z. Mu, C. M. Ma, X. Chen, D. Cvetkovic, A. Pollack, and L. Chen, “MR-guided pulsed high intensity focused ultrasound enhancement of docetaxel combined with radiotherapy for prostate cancer treatment,” Phys. Med. Biol. 57, 535–545 (2012).
16.X. M. Chen, D. Cvetkovic, C.-M. Ma, and L. L. Chen, “Quantitative study of focused ultrasound enhanced doxorubicin delivery to prostate tumor in vivo with MRI guidance,” Med. Phys. 39, 2780–2786 (2012).
17.S. Dromi, V. Frenkel, A. Luk, B. Traughber, M. Angstadt, M. Bur, J. Poff, J. W. Xie, S. K. Libutti, K. C. P. Li, and B. J. Wood, “Pulsed-high intensity focused ultrasound and low temperature sensitive liposomes for enhanced targeted drug delivery and antitumor effect,” Clin. Cancer Res. 13, 2722–2727 (2007).
18.J. A. Poff, C. T. Allen, B. Traughber, A. Colunga, J. W. Xie, Z. Chen, B. J. Wood, C. Van Waes, K. C. P. Li, and V. Frenkel, “Pulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib,” Radiology 248, 485–491 (2008).
21.L. B. Feril, T. Kondo, Z.-G. Cui, Y. Tabuchi, Q.-L. Zhao, H. Ando, T. Misaki, H. Yoshikawa, and S. Umemura, “Apoptosis induced by the sonomechanical effects of low intensity pulsed ultrasound in a human leukemia cell line,” Cancer Lett. 221, 145–152 (2005).
22.A. Jernberg, “Ultrasound, ions and combined modalities for increased local tumor cell death in radiation therapy,” Ph.D. thesis, Karolinska Institute, Stockholm, Sweden, 2007.
23.C.-M. Ma, L. L. Chen, G. Freedman, and R. Bleicher, “MR guided focused ultrasound for high risk and recurrent breast cancer,” in IFMBE Proceedings WC 2009 (IFMBE, Munich, Germany, 2009), Vol. 25/VI, pp. 140–143.
24.Z. Mu, P. Hachem, H. Hensley, R. Stoyanova, H. W. Kwon, A. L. Hanlon, S. Agrawal, and A. Pollack, “Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo,” Prostate 68, 599–609 (2008).
25.R. Stoyanova, P. Hachem, H. Hensley, L. Y. Khor, Z. Mu, M. E. H. Hammond, S. Agrawal, and A. Pollack, “Antisense-MDM2 sensitizes lncap prostate cancer cells to androgen deprivation, radiation, and the combination in vivo,” Int. J. Radiat. Oncol., Biol., Phys. 68, 1151–1160 (2007).
27.X. M. Chen et al., “In vivo evaluation of the therapeutic effects of nonthermal focused ultrasound, radiation and their combination for prostate cancer therapy,” Int. J. Radiat. Oncol., Biol., Phys. 84, S136 (2012).
28.J. F. Zachary, J. P. Blue, R. J. Miller, and W. D. O’Brien, Jr., “Vascular lesions and sthrombomodulin concentrations from auricular arteries of rabbits infused with microbubble contrast agent and exposed to pulsed ultrasound,” Ultrasound. Med. Biol. 32, 1781–1791 (2006).
29.E. J. Hall and A. Giaccia, Radiobiology for the Radiologist, 7th ed. (Lippincott Williams & Wilkins Co, Philadelphia, PA, 2011).
Article metrics loading...
High-intensity focused ultrasound (HIFU) has been investigated for ablative therapy and drug enhancement for gene therapy and chemotherapy. The aim of this work is to explore the feasibility of pulsed focused ultrasound (pFUS) for cancer therapy using an in vivo animal model.
A clinical HIFU system (InSightec ExAblate 2000) integrated with a 1.5 T GE MR scanner was used in this study. Suitable ultrasound parameters were investigated to perform nonthermal sonications, keeping the temperature elevation below 4 °C as measured in real time by MR thermometry. LNCaP cells (106) were injected into the prostates of male mice (n = 20). When tumors reached a diameter of about 5 mm in 3D as measured on magnetic resonance imaging (MRI), the tumor-bearing mice (n = 8) were treated with pFUS (1 MHz frequency; 25 W acoustic power; 0.1 duty cycle; 60 s duration). A total of 4–6 sonications were used to cover the entire tumor volume under MR
image guidance. The animals were allowed to survive for 4 weeks after the treatment. The tumor growth was monitored on high-resolution (0.2 mm) MRI weekly post treatment and was compared with that of the control group (n = 12).
Significant tumor growth delay was observed in the tumor-bearing mice treated with pFUS. The mean tumor volume for the pFUS treated mice remained the same 1 week after the treatment while the mean tumor volume of the control mice grew 42% over the same time. Two weeks after the pFUS treatment, the control group had a mean tumor volume 40% greater than that of the treated group. There was a greater variation in tumor volume at 4 weeks post treatment for both treated and control mice and a slightly faster tumor growth for the pFUS treated mice.
The authors’ results demonstrated that pFUS may have a great potential for cancer therapy. Further experiments are warranted to understand the predominantly nonthermal cell killing mechanisms of pFUS and to derive optimal ultrasound parameters and fractionation schemes to maximize the therapeutic effect of pFUS.
Full text loading...
Most read this month